These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16890330)

  • 21. Improving MMR vaccination rates: herd immunity is a realistic goal.
    Cockman P; Dawson L; Mathur R; Hull S
    BMJ; 2011 Oct; 343():d5703. PubMed ID: 21971162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measles vaccination coverage among five-year-old children: implications for disease elimination in Australia.
    Lawrence GL; MacIntyre CR; Hull BP; McIntyre PB
    Aust N Z J Public Health; 2003; 27(4):413-8. PubMed ID: 14705304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MMR vaccination: answers to some parents' questions.
    Moreton J
    J Fam Health Care; 2002; 12(6):151-3. PubMed ID: 12630143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MMR vaccination: new thought.
    Deshmukh V
    Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
    [No Abstract]   [Full Text] [Related]  

  • 25. Outbreak of measles in primary school students with high first dose MMR vaccination coverage.
    Ong G; Rasidah N; Wan S; Cutter J
    Singapore Med J; 2007 Jul; 48(7):656-61. PubMed ID: 17609829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination vaccine use and vaccination quality in a managed care population.
    Happe LE; Lunacsek OE; Marshall GS; Lewis T; Spencer S
    Am J Manag Care; 2007 Sep; 13(9):506-12. PubMed ID: 17803364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suboptimal MMR2 vaccine coverage in six counties in Norway detected through the national immunisation registry, April 2014 to April 2017.
    Hagerup-Jenssen M; Kongsrud S; Riise ØR
    Euro Surveill; 2017 Apr; 22(17):. PubMed ID: 28489000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.
    Pickering LK; Baker CJ; Freed GL; Gall SA; Grogg SE; Poland GA; Rodewald LE; Schaffner W; Stinchfield P; Tan L; Zimmerman RK; Orenstein WA;
    Clin Infect Dis; 2009 Sep; 49(6):817-40. PubMed ID: 19659433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective cohort study of risk factors for missing preschool booster immunisation.
    Evans MR; Thomas DR
    Arch Dis Child; 1998 Aug; 79(2):141-4. PubMed ID: 9797595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A special immunization clinic tailors vaccinations].
    Aronsson B; Blennow M
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1675-9. PubMed ID: 18590010
    [No Abstract]   [Full Text] [Related]  

  • 31. Evolution of the New Zealand childhood immunisation schedule from 1980: a personal view.
    Reid S
    N Z Med J; 2006 Jun; 119(1236):U2035. PubMed ID: 16807578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the cultural context of MMR rejection a key to an effective public health discourse?
    Cassell JA; Leach M; Poltorak MS; Mercer CH; Iversen A; Fairhead JR
    Public Health; 2006 Sep; 120(9):783-94. PubMed ID: 16828492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health professionals' attitudes to MMR vaccine. Advice in primary care affects parents' decision to take up MMR vaccination.
    Pattison H; Pareek M
    BMJ; 2001 May; 322(7294):1121. PubMed ID: 11360904
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunization status of children under 7 years in the Vikas Nagar area, North India.
    Elliott C; Farmer K
    Child Care Health Dev; 2006 Jul; 32(4):415-21. PubMed ID: 16784497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children.
    Bernsen RM; van der Wouden JC
    Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postlicensure epidemiology of childhood vaccination: the Danish experience.
    Hviid A
    Expert Rev Vaccines; 2006 Oct; 5(5):641-9. PubMed ID: 17181438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting parents' decisions on MMR immunisation: a mixed method investigation.
    Gellatly J; McVittie C; Tiliopoulos N
    Fam Pract; 2005 Dec; 22(6):658-62. PubMed ID: 16024553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in timely vaccination coverage among children living in low-income households.
    Smith PJ; Jain N; Stevenson J; Männikkö N; Molinari NA
    Arch Pediatr Adolesc Med; 2009 May; 163(5):462-8. PubMed ID: 19414693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.